Skip to main content

Advertisement

SpringerLink
Log in

Top practice-changing articles over the last two years

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The field of thromboembolic disease and anticoagulation has had critical advances since the Anticoagulation Forum last met (May of 2011). We summarize our “top ten list” of papers that are likely to change the care of the anticoagulated population and improve their outcomes: (1) Patient self-management of their vitamin K antagonist and self monitoring can decrease thromboembolic events; (2) restarting warfarin after gastrointestinal bleeding may decrease mortality; (3) rivaroxaban is effective in the treatment of pulmonary embolism; either (4) apixaban or (5) low-dose aspirin prevented recurrent venous thromboembolic disease after a standard course of therapy; (6) warfarin prevents thrombotic complications up to at least 90 days after bioprosthetic aortic valve replacement; (7) the relative risk reduction of apixaban compared to warfarin is similar across CHADS2 scores, but the absolute risk reduction is higher in high-risk patients; (8) adherence to a warfarin dose-adjustment algorithm improved time in the therapeutic range and thromboembolic outcomes in the RE-LY trial; (9) warfarin had little benefit (if any) over aspirin in patients with decreased ejection fraction and sinus rhythm; (10) adding clopidogrel to aspirin in patients with lacunar infarcts did not reduce the risk of recurrent stroke and increased bleeding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur AP, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI, Knight E, Kortke H, Levi M, Matchar D, Menendez-Jandula B, Rakovac I, Schaefer C, Siebenhofer A, Souto JC, Sunderji R, Gin K, Shalansky K, Voller H, Wagner O, Zittermann A (2012) Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379(9813):322–334. doi:10.1016/S0140-6736(11)61294-4

    Article  PubMed  Google Scholar 

  2. Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, Dentali F, Crowther MA (2012) Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 172(19):1484–1491. doi:10.1001/archinternmed.2012.4261

    PubMed  CAS  Google Scholar 

  3. Brotman DJ, Jaffer AK (2012) Resuming anticoagulation in the first week following gastrointestinal tract hemorrhage: should we adopt a 4-day rule? Arch Intern Med 172(19):1492–1493. doi:10.1001/archinternmed.2012.4309

    PubMed  Google Scholar 

  4. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297. doi:10.1056/NEJMoa1113572

    Article  PubMed  Google Scholar 

  5. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, American College of Chest Physicians (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S. doi:10.1378/chest.11-2301

    Article  PubMed  CAS  Google Scholar 

  6. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi:10.1056/NEJMoa1007903

    Article  PubMed  CAS  Google Scholar 

  7. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699–708. doi:10.1056/NEJMoa1207541

    Article  PubMed  CAS  Google Scholar 

  8. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367(21):1979–1987. doi:10.1056/NEJMoa1210384

    Article  PubMed  CAS  Google Scholar 

  9. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy–III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308(6923):235–246

    Article  Google Scholar 

  10. Antithrombotic Trialists C (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86

    Article  Google Scholar 

  11. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P (2012) Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366(21):1959–1967. doi:10.1056/NEJMoa1114238

    Article  PubMed  CAS  Google Scholar 

  12. Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C (2012) Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308(20):2118–2125. doi:10.1001/jama.2012.54506

    Article  PubMed  CAS  Google Scholar 

  13. Bonow RO, Carabello BA, Kanu C, De Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114(5):e84–e231. doi:10.1161/circulationaha.106.176857

    Article  PubMed  Google Scholar 

  14. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH (2012) Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e576S–e600S. doi:10.1378/chest.11-2305

    Article  PubMed  CAS  Google Scholar 

  15. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH (2012) Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 380(9855):1749–1758. doi:10.1016/S0140-6736(12)60986-6

    Article  PubMed  CAS  Google Scholar 

  16. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. doi:10.1056/NEJMoa1107039

    Google Scholar 

  17. Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ (2012) Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 126(19):2309–2316. doi:10.1161/circulationaha.112.101808

    Article  PubMed  Google Scholar 

  18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. doi:10.1056/NEJMoa0905561

    Article  PubMed  CAS  Google Scholar 

  19. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184S. doi:10.1378/chest.11-2295

    Article  PubMed  CAS  Google Scholar 

  20. Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF (2003) Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 123(2):499–503

    Article  PubMed  CAS  Google Scholar 

  21. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R (2012) Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 366(20):1859–1869. doi:10.1056/NEJMoa1202299

    Article  PubMed  CAS  Google Scholar 

  22. Hart RG, Pearce LA, Aguilar MI (2007) Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147(8):590–592

    PubMed  Google Scholar 

  23. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806–817. doi:10.1056/NEJMoa1007432

    Article  PubMed  CAS  Google Scholar 

  24. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O’Connor CM, Schulman KA, Teo K, Warren SR (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial. Circulation 119(12):1616–1624. doi:10.1161/circulationaha.108.801753

    Article  PubMed  CAS  Google Scholar 

  25. Kumar G, Goyal MK (2012) Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials. J Stroke Cerebrovasc Dis. doi:10.1016/j.jstrokecerebrovasdis.2012.09.015

    Google Scholar 

  26. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA (2012) Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 367(9):817–825. doi:10.1056/NEJMoa1204133

    Article  PubMed  Google Scholar 

  27. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 108(14):1682–1687. doi:10.1161/01.cir.0000091201.39590.cb

    Article  PubMed  CAS  Google Scholar 

  28. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360(20):2066–2078. doi:10.1056/NEJMoa0901301

    Article  PubMed  Google Scholar 

  29. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431):331–337. doi:10.1016/s0140-6736(04)16721-4

    Article  PubMed  CAS  Google Scholar 

  30. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of 3 months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907. doi:10.1056/NEJM199903253401201

    Article  PubMed  CAS  Google Scholar 

  31. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425–1434. doi:10.1056/NEJMoa035029

    Article  PubMed  CAS  Google Scholar 

  32. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349(18):1713–1721. doi:10.1056/NEJMoa030104

    Article  PubMed  CAS  Google Scholar 

  33. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE (2007) Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357(11):1105–1112. doi:10.1056/NEJMoa067703

    Article  PubMed  CAS  Google Scholar 

  34. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709–718. doi:10.1056/NEJMoa1113697

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hurley Medical Center, One Hurley Plaza, Flint, MI, 48503, USA

    Scott Kaatz

  2. Washington University Medical Center, Box 8005, 660 S. Euclid Avenue, St. Louis, MO, 63110, USA

    Brian F. Gage

Authors
  1. Scott Kaatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian F. Gage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott Kaatz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaatz, S., Gage, B.F. Top practice-changing articles over the last two years. J Thromb Thrombolysis 35, 325–332 (2013). https://doi.org/10.1007/s11239-013-0896-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-013-0896-x

Keywords

Search

Navigation